glp 1 trial Real-World Evidence for GLP-1 Receptor Agonists Across the CKD Spectrum – AJKD Blog The GLP-1 Clinical Trial Landscape

Most dont outright say its because theyre taking weight-loss medications, but in the comments of their social media posts, thats what their followers suspect

Appetite suppression improves, portion control becomes easier, and steady weight reduction may occur

Appetite suppression often occurs within days, leading to early satiety and reduced food intake, though initial weight changes vary widely and are not indicative of long-term results

Cardiac metabolic remodelling in uraemia represents a potential therapeutic target for addressing cardiovascular mortality in CKD

Also see our Top Picks for alpha-lipoic acid

Of note, the effect sizes of GLP-1RA use among patients with any SAH closely resembled what was observable for aSAH patients (cohort 2), suggesting similar efficacy between the 2 populations